stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) EV/FCF
As of 5 November 2026, Genmab A/S Sponsored ADR (GMAB) trades at a EV/FCF of −5.7×. Over the past ten years it has ranged from −6.1× (October 2026) to 232× (November 2021); the current reading is higher than 0% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −3.7× | — |
| FY2024 | 9.9× | (44.03%) |
| FY2023 | 17.7× | (68.06%) |
| FY2022 | 55.3× | (28.52%) |
| FY2021 | 77.3× | 198.77% |
| FY2020 | 25.9× | (25.20%) |
| FY2019 | 34.6× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −3.2× | — |
| Mar 2026 | −3.2× | — |
| Dec 2025 | −3.7× | — |
| Sep 2025 | 13.1× | 24.52% |
| 27 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| RVMD Revolution Medicines, Inc. compare | −25.0× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR | −5.7× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 27.1× |
| RPRX Royalty Pharma PLC compare | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement